Kathleen Sebelius insider trades: Humacyte (HUMA) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Kathleen reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 19, 2026 | HUMA | ↑ Buy | 56,818 | $0.88 | $50K | Direct | May 20, 2026 (1d) |
| Apr 8, 2025 | HUMA | ↑ Buy | 50,000 | $1.32 | $66K | Direct | Apr 8, 2025 (0d) |
| Sep 10, 2024 | HUMA | ↓ Sell | 5,182 | $5.40 | $28K | Direct | Sep 11, 2024 (1d) |
| Jun 12, 2019 | MYOV | ↑ Buy | 5,000 | $8.96 | $45K | Direct | Jun 14, 2019 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other HUMA insiders
Open-market trades in the last 12 months
About Kathleen Sebelius's insider trades
Kathleen Sebelius is a director at Humacyte (HUMA). Since Jun 12, 2019, Kathleen has reported 3 open-market purchases worth $161K and 1 sale worth $28K on SEC Form 4. In the last 12 months: 1 buy ($50K).
Their filings also include grants and awards (25 filings), option exercises (4 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every HUMA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.